AstraZeneca says its antibody cocktail helps prevent COVID-19 for at least 6 months – CTV

November 18, 2021

AstraZeneca on Thursday cemented its lead in bringing a preventative COVID-19 shot to market, saying its antibody cocktail offered 83% protection over six months, providing another possible weapon in the fight against the pandemic.

The therapy, called AZD7442 or Evusheld, had previously been shown to confer 77% protection against symptomatic illness after three months, in an earlier readout of the late-stage PROVENT trial in August.

The data give hope of additional protection for people who do not respond well to vaccines, such as cancer patients.

The Anglo-Swedish company also said a separate study in patients with mild-to-moderate COVID-19 showed a higher dose of AZD7442 cut the risk of symptoms worsening by 88% when given within three days of the first symptoms.

The antibody treatment, enhanced to remain intact in the body for months, is given in one go, as two sequential shots in the arm.

Read more:

NationTalk Partners & Sponsors Learn More